---
title: "ATRX.US (ATRX.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ATRX.US/news.md"
symbol: "ATRX.US"
name: "ATRX.US"
parent: "https://longbridge.com/en/quote/ATRX.US.md"
datetime: "2026-03-14T21:40:23.690Z"
locales:
  - [en](https://longbridge.com/en/quote/ATRX.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ATRX.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ATRX.US/news.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/ATRX.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/ATRX.US/news.md)


# ATRX.US (ATRX.US) — Related News

### [Affinia Therapeutics Granted FDA Fast Track Designation For Aftx-201 As A Treatment For People Living With Bag3-Associated Dilated Cardiomyopathy (Dcm)](https://longbridge.com/en/news/277780747.md)
*2026-03-04T12:45:42.000Z*
### [Addex Therapeutics präsentiert präklinische Daten zu neuem Ansatz bei Angststörungen](https://longbridge.com/en/news/274604920.md)
*2026-02-03T06:00:19.000Z*
### [Ascletis Pharma Doses First Patients in U.S. Phase 2 Trial for Oral GLP-1 Drug](https://longbridge.com/en/news/273633561.md)
*2026-01-26T01:40:52.000Z*
> Ascletis Pharma Doses First Patients in U.S. Phase 2 Trial for Oral GLP-1 Drug

### [Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.](https://longbridge.com/en/news/273626909.md)
*2026-01-26T00:12:32.000Z*
> In the third quarter of 2026, the Phase II study for diabetes treatment is anticipated to reveal its topline data. The A

### [19:10 ET
			
			
				Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes](https://longbridge.com/en/news/273625652.md)
*2026-01-26T00:12:04.000Z*
> Ascletis Pharma Inc. has announced the dosing of the first participants in a 13-week Phase II study of ASC30, an oral GL

### [Genezen and Atsena form strategic manufacturing partnership in Jan 2026. Genezen is a gene therapy CDMO, Atsena is a clinical gene therapy company.](https://longbridge.com/en/news/273090471.md)
*2026-01-20T13:05:22.000Z*
> On January 20, 2026, Genezen, a top gene therapy Contract Development and Manufacturing Organization (CDMO) based in Lex

### [Ascletis Unveils Potent Once-Monthly Triple Agonist ASC37 for Obesity Treatment](https://longbridge.com/en/news/273056579.md)
*2026-01-20T09:00:52.000Z*